185 related articles for article (PubMed ID: 37017320)
1. Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Asada N; Ando J; Takada S; Yoshida C; Usuki K; Shinagawa A; Ishizawa K; Miyamoto T; Iida H; Dobashi N; Okubo S; Honda H; Soshin T; Nishimura Y; Tsutsui A; Mukai H; Yamamoto K
Jpn J Clin Oncol; 2023 Jun; 53(7):595-603. PubMed ID: 37017320
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.
Yamauchi T; Yoshida C; Usuki K; Takada S; Matsumura I; Dobashi N; Miyazaki Y; Miyamoto T; Iida H; Asou N; Kuroda J; Ichikawa S; Komatsu N; Mendes W; Honda H; Okubo S; Kurokawa M; Jiang Q; Wei A; Ishizawa K
Jpn J Clin Oncol; 2021 Aug; 51(9):1372-1382. PubMed ID: 34322703
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Yamamoto K; Shinagawa A; DiNardo CD; Pratz KW; Ishizawa K; Miyamoto T; Komatsu N; Nakashima Y; Yoshida C; Fukuhara N; Usuki K; Yamauchi T; Asada N; Asou N; Choi I; Miyazaki Y; Honda H; Okubo S; Kurokawa M; Zhou Y; Zha J; Potluri J; Matsumura I
Jpn J Clin Oncol; 2022 Jan; 52(1):29-38. PubMed ID: 34739075
[TBL] [Abstract][Full Text] [Related]
4. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].
Hu Y; Jin J; Zhang Y; Hu JD; Li JM; Wei XD; Gao SJ; Zha JH; Jiang Q; Wu J; Mendes W; Wei AH; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):288-294. PubMed ID: 33979972
[No Abstract] [Full Text] [Related]
5. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
[TBL] [Abstract][Full Text] [Related]
6. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
Wang H; Mao L; Yang M; Qian P; Lu H; Tong H; Xie W; Zhou D; Huang X; Wang Y; Xu G; Lu Y; Wei J; Mai W; Ye X; Meng H; Shen Y; Huang J; Yu W; Sun J; Sheng J; Yan X; Jin J; Zhu HH
Lancet Haematol; 2022 Jun; 9(6):e415-e424. PubMed ID: 35512726
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Kadia TM; Reville PK; Wang X; Rausch CR; Borthakur G; Pemmaraju N; Daver NG; DiNardo CD; Sasaki K; Issa GC; Ohanian M; Montalban-Bravo G; Short NJ; Jain N; Ferrajoli A; Bhalla KN; Jabbour E; Takahashi K; Malla R; Quagliato K; Kanagal-Shamanna R; Popat UR; Andreeff M; Garcia-Manero G; Konopleva MY; Ravandi F; Kantarjian HM
J Clin Oncol; 2022 Nov; 40(33):3848-3857. PubMed ID: 35704787
[TBL] [Abstract][Full Text] [Related]
11. Real-world analysis of tumor lysis syndrome in patients started on venetoclax combination for acute myeloid leukemia.
Abernathy KM; Perciavalle MA; Gatwood KS; Chen H; Zakhari MM; Byrne M
J Oncol Pharm Pract; 2023 Sep; 29(6):1326-1333. PubMed ID: 35946111
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Pratz KW; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Döhner H; Récher C; Fiedler W; Yamamoto K; Wang J; Yoon SS; Wolach O; Yeh SP; Leber B; Esteve J; Mayer J; Porkka K; Illés Á; Lemoli RM; Turgut M; Ku G; Miller C; Zhou Y; Zhang M; Chyla B; Potluri J; DiNardo CD
Am J Hematol; 2024 Apr; 99(4):615-624. PubMed ID: 38343151
[TBL] [Abstract][Full Text] [Related]
13. Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Laloi L; Billotey NC; Dumas PY; Paul F; Villate A; Simand C; Fornecker L; Puisset F; Bertoli S; Simonet MB; Laribi K; Houyou D; Santagostino A; Michel C; Guepin GR; Guerineau E; Tabrizi R; Hunault M; Giltat A; Kaphan E; Bulabois C; Cartet E; Rocher C; Lachenal F; Morisset S; Récher C; Pigneux A; Belhabri A; Michallet M; Michallet AS
Cancer Med; 2023 Mar; 12(6):7175-7181. PubMed ID: 36482507
[TBL] [Abstract][Full Text] [Related]
14. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.
Qin Y; Kuang P; Liu T
Clin Exp Med; 2023 Jun; 23(2):219-227. PubMed ID: 35066728
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
Chua CC; Roberts AW; Reynolds J; Fong CY; Ting SB; Salmon JM; MacRaild S; Ivey A; Tiong IS; Fleming S; Brown FC; Loo S; Majewski IJ; Bohlander SK; Wei AH
J Clin Oncol; 2020 Oct; 38(30):3506-3517. PubMed ID: 32687450
[TBL] [Abstract][Full Text] [Related]
17. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).
Wei AH; Panayiotidis P; Montesinos P; Laribi K; Ivanov V; Kim I; Novak J; Stevens DA; Fiedler W; Pagoni M; Bergeron J; Ting SB; Hou JZ; Anagnostopoulos A; McDonald A; Murthy V; Yamauchi T; Wang J; Chyla B; Sun Y; Jiang Q; Mendes W; Hayslip J; DiNardo CD
Blood Cancer J; 2021 Oct; 11(10):163. PubMed ID: 34599139
[TBL] [Abstract][Full Text] [Related]
18. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
DiNardo CD; Jonas BA; Pullarkat V; Thirman MJ; Garcia JS; Wei AH; Konopleva M; Döhner H; Letai A; Fenaux P; Koller E; Havelange V; Leber B; Esteve J; Wang J; Pejsa V; Hájek R; Porkka K; Illés Á; Lavie D; Lemoli RM; Yamamoto K; Yoon SS; Jang JH; Yeh SP; Turgut M; Hong WJ; Zhou Y; Potluri J; Pratz KW
N Engl J Med; 2020 Aug; 383(7):617-629. PubMed ID: 32786187
[TBL] [Abstract][Full Text] [Related]
19. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Brackman D; Eckert D; Menon R; Salem AH; Potluri J; Smith BD; Wei AH; Hayslip J; Miles D; Mensing S; Gopalakrishnan S; Zha J
Hematol Oncol; 2022 Apr; 40(2):269-279. PubMed ID: 35043428
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
